SNS Financial Group LLC Cuts Stock Position in Insulet Co. (NASDAQ:PODD)

SNS Financial Group LLC lessened its stake in shares of Insulet Co. (NASDAQ:PODD) by 7.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 818 shares of the medical instruments supplier’s stock after selling 62 shares during the period. SNS Financial Group LLC’s holdings in Insulet were worth $214,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the stock. Blue Trust Inc. raised its holdings in Insulet by 84.1% in the third quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier’s stock worth $30,000 after buying an additional 58 shares during the last quarter. Raymond James & Associates raised its holdings in Insulet by 3.8% in the 3rd quarter. Raymond James & Associates now owns 37,456 shares of the medical instruments supplier’s stock worth $8,718,000 after acquiring an additional 1,367 shares during the last quarter. Private Advisor Group LLC raised its holdings in Insulet by 131.8% in the 3rd quarter. Private Advisor Group LLC now owns 7,387 shares of the medical instruments supplier’s stock worth $1,719,000 after acquiring an additional 4,200 shares during the last quarter. Lecap Asset Management Ltd. lifted its position in Insulet by 25.2% in the 3rd quarter. Lecap Asset Management Ltd. now owns 4,560 shares of the medical instruments supplier’s stock valued at $1,061,000 after acquiring an additional 918 shares in the last quarter. Finally, Greenleaf Trust boosted its stake in Insulet by 4.2% during the 3rd quarter. Greenleaf Trust now owns 1,783 shares of the medical instruments supplier’s stock valued at $415,000 after purchasing an additional 72 shares during the last quarter.

Insulet Stock Performance

Shares of PODD opened at $288.29 on Friday. The business has a 50-day simple moving average of $272.71 and a two-hundred day simple moving average of $246.47. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21. Insulet Co. has a 52 week low of $160.19 and a 52 week high of $289.46. The stock has a market cap of $20.22 billion, a price-to-earnings ratio of 49.36, a PEG ratio of 3.52 and a beta of 1.23.

Insulet (NASDAQ:PODD) last released its earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.00 by $0.15. Insulet had a net margin of 21.22% and a return on equity of 27.98%. On average, analysts expect that Insulet Co. will post 3.22 EPS for the current year.

Insider Transactions at Insulet

In other news, EVP Eric Benjamin sold 12,394 shares of the company’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total value of $3,470,320.00. Following the completion of the transaction, the executive vice president now owns 11,383 shares of the company’s stock, valued at $3,187,240. This represents a 52.13 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CAO Lauren Budden sold 915 shares of Insulet stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $275.62, for a total value of $252,192.30. Following the sale, the chief accounting officer now directly owns 5,733 shares in the company, valued at $1,580,129.46. This trade represents a 13.76 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.47% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently weighed in on the company. Citigroup boosted their price target on Insulet from $283.00 to $310.00 and gave the stock a “buy” rating in a research note on Wednesday, December 11th. Morgan Stanley boosted their target price on Insulet from $234.00 to $317.00 and gave the stock an “overweight” rating in a research report on Monday, November 11th. Sanford C. Bernstein assumed coverage on shares of Insulet in a research note on Wednesday, November 6th. They issued an “outperform” rating and a $300.00 price target for the company. Barclays increased their price objective on shares of Insulet from $220.00 to $234.00 and gave the company an “equal weight” rating in a research report on Monday, November 11th. Finally, BTIG Research lifted their target price on shares of Insulet from $260.00 to $270.00 and gave the stock a “buy” rating in a research report on Friday, November 8th. Two analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $277.13.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.